Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19184830 | PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64 | April 2025 | July 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19180813 | BIOORTHOGONAL COMPOSITIONS | April 2025 | December 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 19080259 | METHOD OF INHIBITING CANCER CELL VIABILITY | March 2025 | June 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18983625 | GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18932511 | NOVEL GENE DELIVERY AGENTS | October 2024 | August 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18930419 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | October 2024 | July 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18905806 | FORMULATION OF EAR DROPS AND METHODS FOR DELIVERY THEREOF FOR TREATING UPPER RESPIRATORY INFECTIONS | October 2024 | April 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18745896 | PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64 | June 2024 | March 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18745906 | COPPER-64 COMPOSITIONS AND FORMULATIONS | June 2024 | October 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18733537 | PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64 | June 2024 | August 2025 | Allow | 14 | 3 | 0 | Yes | Yes |
| 18655741 | COMPOSITION OF RADIOACTIVE AND NON-RADIOACTIVE MICROPARTICLES | May 2024 | November 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18646526 | MULTI-MODE IMAGING MARKERS | April 2024 | December 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18614094 | RADIOPHARMACEUTICAL CONJUGATE COMPOUND FOR DIAGNOSIS AND/OR THERAPEUTIC USES THEREOF | March 2024 | October 2025 | Allow | 19 | 3 | 1 | Yes | No |
| 18610095 | METHOD OF PREVENTING THE DEVELOPMENT OF MELANOMA | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18604397 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | March 2024 | August 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18438751 | COMPOSITION CONTAINING BUFFER | February 2024 | March 2026 | Allow | 25 | 2 | 0 | No | No |
| 18428591 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | January 2024 | March 2025 | Allow | 13 | 0 | 0 | No | No |
| 18511854 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | November 2023 | February 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18499758 | METHODS AND KITS FOR PREPARING RADIONUCLIDE COMPLEXES | November 2023 | August 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18493909 | DEVICE AND CASSETTE FOR PERFORMING A PLURALITY OF SYNTHESIS PROCESSES OF PREPARING A RADIOPHARMACEUTICAL IN SERIES | October 2023 | February 2026 | Allow | 27 | 1 | 1 | Yes | No |
| 18238951 | PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64 | August 2023 | July 2024 | Allow | 11 | 1 | 1 | Yes | No |
| 18238972 | PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64 | August 2023 | October 2024 | Allow | 14 | 3 | 0 | No | No |
| 18238966 | PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64 | August 2023 | March 2024 | Allow | 7 | 1 | 0 | No | No |
| 18448682 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | August 2023 | September 2024 | Allow | 13 | 0 | 0 | Yes | No |
| 18232013 | METHOD OF PREVENTING THE DEVELOPMENT OF MELANOMA | August 2023 | October 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18365555 | PHARMACEUTICAL COMPOSITION CONTAINING TAXANE NANOAGGREGATES AND USE THEREOF | August 2023 | October 2025 | Allow | 26 | 5 | 0 | Yes | No |
| 18363369 | METHODS AND REAGENTS FOR TUMOR TARGETING WITH GREATER EFFICACY AND LESS TOXICITY | August 2023 | December 2024 | Allow | 17 | 0 | 0 | Yes | No |
| 18352435 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | July 2023 | January 2026 | Abandon | 30 | 1 | 1 | No | No |
| 18213194 | PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64 | June 2023 | March 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18339195 | ENGINEERED RADIOACTIVE POLYMERIC MICROSPHERE, AND PREPARATION AND APPLICATION THEREOF | June 2023 | September 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18205751 | METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASES | June 2023 | April 2025 | Allow | 22 | 1 | 0 | No | No |
| 18203326 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | May 2023 | February 2025 | Allow | 21 | 0 | 1 | Yes | No |
| 18324420 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | May 2023 | September 2023 | Allow | 4 | 1 | 0 | No | No |
| 18199311 | PLASTIC CONTAINERS | May 2023 | March 2026 | Abandon | 34 | 2 | 0 | No | No |
| 18142378 | FLUORESCENT DYE FOR PROTEIN OR NUCLEIC ACID LABELLING | May 2023 | March 2026 | Allow | 34 | 0 | 0 | Yes | No |
| 18303708 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | April 2023 | June 2024 | Allow | 14 | 2 | 0 | Yes | No |
| 18175246 | Long-Lived Gadolinium Based Tumor Targeted Imaging and Therapy Agents | February 2023 | October 2025 | Allow | 32 | 2 | 0 | Yes | No |
| 18161395 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | January 2023 | September 2024 | Allow | 20 | 0 | 0 | Yes | No |
| 18156319 | ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | January 2023 | August 2023 | Allow | 7 | 0 | 0 | Yes | No |
| 18150542 | Granzyme B Directed Imaging and Therapy | January 2023 | November 2024 | Allow | 22 | 0 | 0 | No | No |
| 18003659 | DOTA-HAPTEN COMPOSITIONS FOR ANTI-DOTA/ANTI-TUMOR ANTIGEN BISPECIFIC ANTIBODY PRETARGETED RADIOIMMUNOTHERAPY | December 2022 | December 2025 | Allow | 36 | 0 | 0 | No | No |
| 18001384 | GRANZYME B DIRECTED IMAGING AND THERAPY | December 2022 | October 2025 | Allow | 34 | 0 | 0 | No | No |
| 18063349 | LIQUID VEHICLE FOR ENTEROGRAPHY EXAMINATION | December 2022 | June 2025 | Allow | 30 | 1 | 0 | Yes | No |
| 17993186 | PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64 | November 2022 | August 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 18056856 | IMAGING METHODS USING DEUTERATED COMPOUNDS | November 2022 | September 2024 | Allow | 22 | 1 | 0 | No | No |
| 17979367 | NEW GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | November 2022 | August 2025 | Allow | 33 | 3 | 0 | No | No |
| 18051422 | PRISTINE GRAPHENE BASED BIOSENSOR FOR BIOMARKER DETECTION AND RELATED CORE PARTICLES, MATERIALS COMPOSITIONS METHODS AND SYSTEMS | October 2022 | June 2025 | Allow | 31 | 1 | 1 | Yes | No |
| 17976664 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | October 2022 | April 2023 | Allow | 5 | 0 | 0 | Yes | No |
| 17969297 | METHOD OF PREVENTING THE DEVELOPMENT OF MELANOMA | October 2022 | March 2023 | Allow | 5 | 0 | 0 | Yes | No |
| 17959278 | BIOGENIC HEMIN-BASED MRI CONTRAST AGENTS, AND COMPOSITIONS AND METHODS THEREOF | October 2022 | July 2025 | Allow | 34 | 2 | 0 | No | No |
| 17933234 | NOVEL HETEROAROMATIC SILICON-FLUORIDE-ACCEPTORS USEFUL FOR 18F LABELING OF MOLECULES AND BIOMOLECULES, AND METHODS OF PREPARING SAME | September 2022 | March 2025 | Allow | 30 | 1 | 0 | No | No |
| 17943754 | STRUCTURAL DESIGN OF A CRANIAL NERVE DEGENERATION CONTRAST AGENT PRECURSORS | September 2022 | June 2025 | Allow | 33 | 0 | 0 | No | No |
| 17908630 | BORON CARRYING AGENT FOR INTEGRATED TUMOR DIAGNOSIS AND TREATMENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | September 2022 | November 2025 | Allow | 38 | 0 | 0 | Yes | No |
| 17901072 | TRIARYL METHANE COMPOSITION, DYE COMPOSITION FOR OCULAR MEMBRANE DYEING | September 2022 | March 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17894874 | PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64 | August 2022 | November 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17892769 | NOVEL PEPTIDE-BASED CANCER IMAGING AGENTS | August 2022 | February 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17889655 | DOUBLE-LABELED PROBE FOR MOLECULAR IMAGING AND USE THEREOF | August 2022 | August 2024 | Allow | 24 | 0 | 0 | Yes | No |
| 17884751 | METHODS OF IMAGING AND DELIVERING THERAPEUTIC AGENTS | August 2022 | April 2025 | Abandon | 33 | 0 | 1 | No | No |
| 17881895 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | August 2022 | November 2024 | Allow | 27 | 1 | 0 | No | No |
| 17794843 | NOVEL GADOLINIUM-BASED COMPOUND, METHOD FOR PRODUCING SAME, AND MRI CONTRAST AGENT CONTAINING SAME | July 2022 | May 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17864671 | FUNCTIONALIZED NANOPARTICLES AND METHODS OF MAKING AND USING SAME | July 2022 | July 2025 | Allow | 37 | 0 | 2 | Yes | No |
| 17858859 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | July 2022 | September 2022 | Allow | 2 | 0 | 0 | No | No |
| 17810956 | RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R | July 2022 | August 2025 | Allow | 38 | 2 | 0 | No | No |
| 17857990 | METHODS AND KITS FOR PREPARING RADIONUCLIDE COMPLEXES | July 2022 | October 2023 | Allow | 15 | 3 | 0 | Yes | No |
| 17810316 | Macrocyclic Chelators and Methods of Use Thereof | June 2022 | February 2025 | Allow | 31 | 1 | 0 | Yes | No |
| 17786980 | ECO-FRIENDLY SMART PHOTOSENSITIZER AND PHOTO-STEM CELL THERAPY PRODUCT COMPRISING SAME | June 2022 | March 2023 | Allow | 9 | 0 | 0 | Yes | No |
| 17803382 | Borylated amino acid compositions for use in boron neutron capture therapy and methods thereof | June 2022 | June 2024 | Allow | 24 | 0 | 0 | Yes | No |
| 17750333 | DOTMP KIT FORMULATIONS FOR RADIOISOTOPES | May 2022 | December 2024 | Allow | 31 | 1 | 0 | Yes | No |
| 17734647 | TUMOR-TARGETING, CLEARABLE HUMAN PROTEIN-BASED MRI NANOPROBES, AND COMPOSITIONS AND METHODS THEREOF | May 2022 | February 2026 | Allow | 46 | 3 | 0 | No | No |
| 17769986 | METHODS AND COMPOSITIONS FOR TREATING ENDOMETRIOSIS | April 2022 | August 2024 | Allow | 28 | 2 | 1 | Yes | Yes |
| 17722727 | SUPERPARAMAGNETIC GOLD NANOPARTICLE CLUSTER-PROTEIN NANOPARTICLE FUSION BODY FOR MAGNETIC RESONANCE IMAGING AND MAGNETIC THERMOTHERAPY | April 2022 | March 2026 | Abandon | 47 | 1 | 0 | No | No |
| 17700913 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | March 2022 | November 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17697426 | NATURAL CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | March 2022 | July 2023 | Abandon | 16 | 1 | 1 | No | No |
| 17692289 | COMPOSITIONS AND METHODS FOR REMOVING BIO-SYNTHETIC NANO-PARTICLES FROM BODILY FLUIDS | March 2022 | April 2023 | Abandon | 13 | 2 | 1 | Yes | Yes |
| 17682695 | COMPOUNDS FOR USE AS IRON(III) MRI CONTRAST AGENTS | February 2022 | September 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17678782 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | February 2022 | November 2024 | Allow | 33 | 0 | 1 | Yes | No |
| 17678803 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | February 2022 | June 2024 | Allow | 27 | 0 | 0 | Yes | No |
| 17665202 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | February 2022 | July 2022 | Allow | 5 | 0 | 1 | Yes | No |
| 17590504 | ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | February 2022 | December 2022 | Allow | 11 | 1 | 1 | Yes | No |
| 17622058 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USES THEREOF | December 2021 | November 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17553113 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY | December 2021 | April 2025 | Allow | 40 | 2 | 0 | Yes | No |
| 17550731 | BIOORTHOGONAL COMPOSITIONS | December 2021 | August 2024 | Allow | 32 | 0 | 1 | Yes | No |
| 17532083 | METHOD OF PREPARING ZIRCONIUM-89 OXINE COMPLEX | November 2021 | July 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17532109 | ZIRCONIUM-89 OXINE COMPLEX AS A CELL LABELING AGENT FOR POSITRON EMISSION TOMOGRAPHY | November 2021 | November 2025 | Allow | 48 | 3 | 0 | Yes | No |
| 17518794 | SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | November 2021 | December 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17451536 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | October 2021 | November 2023 | Allow | 25 | 0 | 0 | Yes | No |
| 17450212 | TAU PET IMAGING LIGANDS | October 2021 | February 2024 | Allow | 28 | 1 | 0 | Yes | No |
| 17494367 | RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY | October 2021 | January 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17492260 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | October 2021 | February 2025 | Allow | 41 | 2 | 0 | No | No |
| 17448463 | Half-Curcuminoids as Amyloid-Beta PET Imaging Agents | September 2021 | August 2024 | Allow | 35 | 1 | 0 | Yes | No |
| 17480924 | Half-Curcuminoids as Amyloid-Beta PET Imaging Agents | September 2021 | February 2024 | Allow | 29 | 1 | 0 | Yes | No |
| 17473820 | MULTI-MODE IMAGING MARKERS | September 2021 | January 2024 | Allow | 28 | 0 | 0 | Yes | No |
| 17466443 | PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64 | September 2021 | August 2022 | Allow | 12 | 2 | 1 | Yes | No |
| 17403429 | Methods of Imaging and Delivering Therapeutic Agents | August 2021 | December 2021 | Allow | 4 | 0 | 0 | Yes | No |
| 17392453 | METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASES | August 2021 | January 2024 | Allow | 30 | 1 | 0 | Yes | No |
| 17389674 | NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES | July 2021 | April 2024 | Allow | 32 | 1 | 0 | Yes | No |
| 17443863 | ASCORBATE FORMULATIONS AND METHODS OF USE AS CONTRAST AGENTS | July 2021 | January 2025 | Allow | 42 | 2 | 0 | Yes | No |
| 17379011 | MULTINUCLEAR COMPLEXES AND THEIR PREPARATION | July 2021 | April 2023 | Allow | 21 | 3 | 1 | Yes | No |
| 17352647 | METHOD FOR PREPARATION OF HIGHLY POLARIZED NUCLEAR SPINS CONTAINING SAMPLES AND USES THEREOF FOR NMR AND MRI | June 2021 | February 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17350304 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | June 2021 | October 2024 | Allow | 40 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SAMALA, JAGADISHWAR RAO.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 22.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SAMALA, JAGADISHWAR RAO works in Art Unit 1618 and has examined 1,096 patent applications in our dataset. With an allowance rate of 70.0%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 30 months.
Examiner SAMALA, JAGADISHWAR RAO's allowance rate of 70.0% places them in the 32% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by SAMALA, JAGADISHWAR RAO receive 1.59 office actions before reaching final disposition. This places the examiner in the 30% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by SAMALA, JAGADISHWAR RAO is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +54.5% benefit to allowance rate for applications examined by SAMALA, JAGADISHWAR RAO. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.9% of applications are subsequently allowed. This success rate is in the 34% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 36.7% of cases where such amendments are filed. This entry rate is in the 55% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 71.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 59% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 76.2% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 64.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 64.8% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 7.2% of allowed cases (in the 90% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.